ChinaBio Today -- In an annual review of its business plans, Eli Lilly revealed China’s pharmaceutical market will be a top priority for the company. Lilly has reorganized its corporate structure so that one of its six units would be devoted to emerging markets, and this unit will aim at taking advantage of the expected growth in China. Because one-third of worldwide growth in pharmaceutical markets will come from emerging markets, Lilly decided to recognize the importance of these new markets in its corporate goals. More details...
